SkinBioTherapeutics (LON:SBTX) Trading 4.8% Higher – What’s Next?

Shares of SkinBioTherapeutics plc (LON:SBTX) rose 4.8% during trading on Tuesday . The stock traded as high as GBX 5.50 and last traded at GBX 5.50. Approximately 774,704 shares were traded during trading, a decline of 86% from the average daily volume of 5,671,399 shares. The stock had previously closed at GBX 5.25.

SkinBioTherapeutics Price Performance

The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The stock’s 50 day moving average price is GBX 16.37 and its two-hundred day moving average price is GBX 15.68. The firm has a market capitalization of £15.77 million, a price-to-earnings ratio of -19.65 and a beta of 2.01.

SkinBioTherapeutics (LON:SBTX) last announced its earnings results on Monday, December 8th. The company reported GBX (0.31) EPS for the quarter. SkinBioTherapeutics had a negative return on equity of 115.86% and a negative net margin of 237.95%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.